Thyrocare Q4 FY26 PAT Surges 128% YoY

Thyrocare reported Q4 FY26 consolidated revenue growth of 20% YoY to INR 224 crores, with PAT surging 128% to INR 48.7 crores.
The company processed 210 million tests in FY26, a 23% YoY increase, supported by a network of 10,800 franchisees and 40 labs.
Strategic expansion into genomics and specialty testing began, alongside a recommended final dividend of INR 7 per equity share.
Management provided a growth outlook in the mid-to-high teens for FY27, focusing on franchise expansion and new specialty segments.